ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $21,133.86 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $9.02, for a total value of $21,133.86. Following the transaction, the insider now owns 1,745,082 shares of the company’s stock, valued at $15,740,639.64. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.00, for a total value of $3,996.00.
• On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total value of $890,977.56.
• On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.01, for a total value of $6,307.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY opened at $9.96 on Thursday. The stock has a market capitalization of $961.14 million, a PE ratio of -17.47 and a beta of 0.78. The business has a fifty day moving average price of $7.75 and a two-hundred day moving average price of $5.80. ARS Pharmaceuticals, Inc. has a fifty-two week low of $2.55 and a fifty-two week high of $10.20.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SPRY. RA Capital Management L.P. raised its holdings in ARS Pharmaceuticals by 214.3% in the 3rd quarter. RA Capital Management L.P. now owns 9,459,678 shares of the company’s stock valued at $35,758,000 after acquiring an additional 6,450,000 shares in the last quarter. Charles Schwab Trust Co acquired a new position in ARS Pharmaceuticals in the 3rd quarter valued at $16,050,000. BlackRock Inc. acquired a new position in ARS Pharmaceuticals in the 2nd quarter valued at $15,148,000. Sectoral Asset Management Inc. acquired a new position in ARS Pharmaceuticals in the 2nd quarter valued at $8,413,000. Finally, Nantahala Capital Management LLC raised its holdings in ARS Pharmaceuticals by 45.3% in the 4th quarter. Nantahala Capital Management LLC now owns 1,596,504 shares of the company’s stock valued at $8,749,000 after acquiring an additional 497,429 shares in the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on SPRY shares. Wedbush restated an “outperform” rating and issued a $19.00 price target on shares of ARS Pharmaceuticals in a research note on Monday, March 11th. Leerink Partnrs upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th. SVB Leerink upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $6.00 to $18.00 in a research note on Tuesday, March 5th. Finally, William Blair upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.